Finerenone lowers CV risk in patients with CKD, T2D
12 Dec 2020
byElaine Soliven
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Finerenone lowers CV risk in patients with CKD, T2D
12 Dec 2020
